Latest Conference Coverage

Over a 12-week trial period, Asian patients treated with brivaracetam demonstrated efficacy and safety outcomes that were similar to other populations previously observed.

In an analysis of lacosamide in pregnant women, a low number of preterm birth deliveries were reported, with no new safety concerns identified.

The director of the Mid-Atlantic Epilepsy & Sleep Center and adjunct associate professor of neurology at George Washington University discussed the advancements in epilepsy research, especially for drug-resistant epilepsy, to be presented at AES 2023. [WATCH TIME: 4 minutes]

Both pediatric and adult patients with tuberous sclerosis complex demonstrated significant reductions in TSC-associated seizures with no new safety concerns identified.

The division director of epilepsy and associate professor of neurology at The Ohio State University Wexner Medical Center discussed the profound repercussion of ongoing seizures for patients with epilepsy which is to be presented at AES 2023 in SK Life Science’s symposium. [WATCH TIME: 5 minutes]

Heather Synder, PhD, vice president of medical and scientific relations at the Alzheimer’s Association, gave thoughts on the recently concluded CTAD conference and how the organization plans to carry the positive momentum in the field.

The associate professor in the department of neurology at Mayo Clinic College of Medicine talked about findings from a real-world study assessing eptinezumab among patients with chronic migraine which was presented at the AHS Scottsdale Headache Symposium 2023. [WATCH TIME: 4 minutes]

Alvaro Pascual-Leone, MD, PhD, director of the Berenson-Allen Center for Noninvasive Brain Stimulation at Beth Israel Deaconess Medical Center, provided commentary on the ways Alzheimer disease treatment has changed and how clinicians will need to adapt in the coming years.

The director of the Banner Sun Health Research Institute provided commentary on his presentation at CTAD 2023 examining the value of donanemab and its effect on specific Alzheimer-related assessments. [WATCH TIME: 10 minutes]

The director of disability policy at the Muscular Dystrophy Association talked about the future possibility of having an aircraft that accommodates for patients with neuromuscular disorders who use mobility devices. [WATCH TIME: 3 minutes]

The director of the headache section at Cleveland Clinic’s Neurological Institute provided commentary on the advances in the field of migraine and reasons to be excited about the 2023 AHS symposium in Scottsdale, Arizona. [WATCH TIME: 3 minutes]

The associate professor in the department of neurology and neurosurgery at McGill University discussed results from a study on the long-term use of continuous positive airway pressure treatment among patients with multiple sclerosis and sleep apnea presented at MSMilan 2023. [WATCH TIME: 5 minutes]

The research neuroscientist at the University of California Berkeley provided insight on findings from the US POINTER study and why previous thoughts on the link between relevant biomarkers and cognition may be slightly incorrect.

The neuromuscular neurologist at the Cleveland Clinic discussed findings from an analysis presented at AANEM 2023 that investigated the safety and efficacy of subcutaneous efgartigimod in patients with myasthenia gravis. [WATCH TIME: 5 minutes]

Group-level analyses indicated that a combination of cipaglucosidase alfa and miglustat outperformed alglucosidase alfa/placebo in various motor function and patient-reported outcome measures, with notable improvements in walking tests and quality of life aspects like 'ability to move around' and 'energy level.'

The associate director of the Alzheimer’s Disease Research Unit at the Yale School of Medicine discussed the mechanism of action of ALX-001, a highly selective agent in development for neurodegenerative diseases. [WATCH TIME: 5 minutes]

The professor of neurology, psychiatry, and pharmacology at the NYU Grossman School of Medicine commented on the differences in mechanisms and clinical trial data between lecanemab and donanemab. [WATCH TIME: 5 minutes]

Kevin Church, PhD, chief scientific officer at Athira Pharma, discussed preclinical findings of fosgonimeton where the therapy exhibited procognitive effects among mice models in Alzheimer disease, as presented at CTAD 2023.

The founder of Strategic Advocacy Solutions LLC discussed the critical role of psychosocial support throughout various stages of neuromuscular diseases, emphasizing the impact of transitions on patients' emotional well-being. [WATCH TIME: 5 minutes]

Brendon Yee, PhD, a respiratory and sleep physician at the Woolcock Institute of Medical Research, discussed findings from a recent phase 1 trial presented at World Sleep Congress 2023 in which ALKS 2680 demonstrated improvements in wakefulness among patients with narcolepsy type 1.

The director of the neuromuscular diseases division at the University of Washington discussed findings from a new post hoc analysis presented at AANEM 2023 that showed that zilucoplan treatment significantly reduced fatigue in patients with myasthenia gravis. [WATCH TIME: 6 minutes]

The chief scientific officer at Athira Pharma talked about new preclinical results presented at the 2023 NEALS Annual Meeting on the investigational therapy ATH-1105 for patients with amyotrophic lateral sclerosis. [WATCH TIME: 5 minutes]

Recent findings from an analysis of the CHAMPION MG study suggest that ravulizumab continues to be an effective therapy for patients with generalized myasthenia gravis, regardless of whether they had received prior IVIg treatment.

The vice president of Innovation and New Technologies at Grifols provided perspective on the interim phase 2 findings of ABvac40, a vaccine in development for patients with Alzheimer disease. [WATCH TIME: 3 minutes]

The chief medical officer of NeuroTherapia provided insight on promising phase 1b data assessing NTRX-07, a CBR2-targeting agent in development for patients with early-stage Alzheimer disease.

The professor and chair of neurology at Virginia Commonwealth University discussed a study conducted among neurologists that revealed healthcare disparities in the treatment of myasthenia gravis, particularly related to access to care and therapeutics. [WATCH TIME: 5 minutes]

Recent research, presented at the 2023 AANEM Annual Meeting, emphasized the potential need for patient support programs targeting at-risk populations to enhance disease management and reduce acute care utilization in myasthenia gravis.

The director of disability policy at the Muscular Dystrophy Association discussed his lecture at AANEM 2023 on how clinicians can advocate for their patients to help improve accessibility and health equity. [WATCH TIME: 7 minutes]